Literature DB >> 1398741

Human C5a anaphylatoxin: gene cloning and expression in Escherichia coli.

W Bautsch1, M Emde, T Kretzschmar, J Köhl, D Suckau, D Bitter-Suermann.   

Abstract

A gene coding for the human anaphylatoxin C5a was cloned and expressed in Escherichia coli. A combination of reverse transcription of mRNA of the U937 cell line with subsequent preparative polymerase chain reaction was employed to obtain the gene. The sequence was cloned into the plasmid vector pKK 233-2 behind an ATG initiation codon under the control of a trc promotor. After purification by ion exchange chromatography and reversed phase FPLC a mixture of predominantly non-glycosylated recombinant human C5a with a beta-mercaptoethanol adduct at cysteine 27 and the N-methionyl derivative was obtained which was homogeneous on silver-stained gels, immunoreactive with C5a-specific monoclonal antibodies and functionally active in releasing myeloperoxidase from human granulocytes and ATP from guinea pig platelets. The final yield was about 0.4-0.8 mg purified recombinant C5a per liter bacterial culture.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1398741     DOI: 10.1016/S0171-2985(11)80316-5

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  2 in total

1.  Pharmacological characterization of antagonists of the C5a receptor.

Authors:  N J Paczkowski; A M Finch; J B Whitmore; A J Short; A K Wong; P N Monk; S A Cain; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.

Authors:  W Bautsch; T Kretzschmar; T Stühmer; A Kola; M Emde; J Köhl; A Klos; D Bitter-Suermann
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.